Composition for inhibiting bacteria, resisting inflammation, relieving inflammation and repairing sensitive skin

Abstract

The invention discloses a composition for inhibiting bacteria, resisting inflammation, relieving inflammation and repairing sensitive skin. The composition comprises the following components in parts by weight: 1-5 parts of a sophora flavescens extract; 2-15 parts of a radix scutellariae extract; 5-10 parts of a white peony root extract; 0.2 to 5 parts of a grapefruit extract; and 1-5 parts of pomegranate extract. The composition prepared from the radix sophorae flavescentis extract, the radix scutellariae extract, the radix paeoniae alba extract, the grapefruit extract and the pomegranate extract takes sophocarpidine, baicalin, paeoniflorin, naringin and punicalagin as main functional components to play a synergistic effect, so that the composition has very remarkable effects of inhibiting bacteria, resisting inflammation, relieving inflammation and repairing sensitive skin.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of cosmetics, and particularly relates to a composition for inhibiting bacteria, resisting inflammation, relieving inflammation and repairing sensitive skin. BACKGROUND

[0002] In recent years, due to environmental pollution, improper skin care, unhealthy lifestyle, increased work and life pressure and other factors, the number of people with sensitive skin problems or skin itching problems has increased dramatically, and skin sensitivity problems have attracted more and more attention, and the incidence of skin sensitivity problems continues to rise. According to the International Forum on the Biology of Itching (IFSI) and the Chinese Expert Consensus on Sensitive Skin (2017 version), sensitive skin is defined as a syndrome in which the skin appears to be paroxysmal or periodic burning, redness, stinging, itching and tightness after being stimulated by the outside world, with or without persistent erythema. Sensitive skin is a syndrome of subjective and objective symptoms that occurs after the skin is stimulated by the outside world. Sensitive skin is most likely to occur on the face and is a highly intolerant skin condition. After being stimulated by some small stimuli such as temperature changes, seasonal changes, chemicals, and the mind, the skin may exhibit varying degrees of burning, paroxysmal redness, stinging, itching, and other symptoms, with or without erythema, and often cannot tolerate ordinary skin care products, causing great distress to people with problems. The demand for relieving inflammation and repairing sensitive skin is growing. The Chinese Clinical Diagnosis and Treatment Guide for Sensitive Skin (2024 version) is based on the 2017 version and combines the latest research progress to develop relevant guidelines for the definition, pathogenesis, clinical evaluation and classification, and prevention and treatment of sensitive skin, with the aim of improving the level of clinical diagnosis and treatment of sensitive skin.

[0003] Current research suggests that the mechanism of sensitive skin is a complex process involving skin barrier, neurovascular response and innate immune inflammation. In addition, skin microecological disorders are also involved, and the clinical manifestations include impaired skin barrier function, increased neurovascular reactivity, immune inflammation, and microecological disorders. The evaluation of sensitive skin mainly includes subjective, semi-subjective and objective evaluation. Subjective evaluation often uses sensitive skin self-assessment scale, micro-stimulation and sensitive skin symptom assessment scale, and BoSS (burden of sensitive skin) questionnaire. Semi-subjective evaluation is widely used, mainly including stimulation test, such as lactic acid stinging test and capsaicin test. Due to the different mechanisms of various chemical stimuli and transmission pathways, it can help diagnose different types of sensitive skin.

[0004] With societal progress, consumers are increasingly aware of product ingredients and prefer natural and safe skincare products. For those with sensitive skin, functional skincare products containing plant-based active ingredients are a good choice. Soothing products using natural plant extracts, especially those from traditional Chinese medicine, as active ingredients have significant development potential. Based on thousands of years of traditional Chinese medicine experience and theory, and drawing on internationally recognized pharmaceutical standards and regulations, modern scientific theories are used to research the effective components of traditional Chinese medicine. Currently, the ingredients on the market for soothing inflammation and repairing sensitive skin are usually either single active ingredients or compound formulations. Single-ingredient products and compound anti-allergy agents each have their advantages and disadvantages. Long-term use of single-ingredient products can easily lead to drug resistance and significantly reduced effectiveness. For compound anti-allergy agents, the compatibility and stability of different substances vary greatly. Inappropriate combinations can lead to decreased effectiveness and reduced stability. Compounding multiple plant extracts further tests the technical level of researchers. With complex ingredients and unclear active components, stability issues such as discoloration and precipitation are more likely to occur. Therefore, developing a soothing agent with clearly defined, safe, and effective plant-derived ingredients is particularly important and has practical application value. Summary of the Invention

[0005] In view of the shortcomings of the prior art, the purpose of this invention is to provide a composition that has antibacterial and anti-inflammatory properties, soothes inflammation, and repairs sensitive skin.

[0006] The original formula of the ancient Chinese medicine prescription "Kushen Tang" mainly consists of Sophora flavescens, rhubarb, Scutellaria baicalensis, Coptis chinensis, peony root, Phellodendron chinense, and Cnidium monnieri, and is often used to treat skin diseases such as sores, malnutrition, and rashes in children, as well as heat sores on the face and head. However, when this ancient prescription is applied to cosmetics, many of its ingredients have poor solubility, making it unsuitable for use. Based on this, this invention modifies the ancient prescription, taking the principal herb Sophora flavescens, the assistant herb Scutellaria baicalensis, and the adjuvant herb Peony root (white peony root) from "Kushen Tang," and directly adding grapefruit extract and pomegranate extract to the extracts of these three herbs. Through the compounding of these five herbal extracts, a composition with antibacterial, anti-inflammatory, anti-inflammatory, and sensitive skin repair effects is prepared.

[0007] The objective of this invention is achieved through the following technical solution: In a first aspect, the present invention provides a composition for antibacterial and anti-inflammatory purposes, soothing inflammation, and repairing sensitive skin, comprising the following components in parts by weight: 1-5 parts of Sophora flavescens extract; Scutellaria baicalensis extract 2-15 parts; 5-10 parts of white peony extract; Grapefruit extract 0.2-5 parts; 1-5 parts of pomegranate extract.

[0008] Preferably, the composition for antibacterial, anti-inflammatory, soothing, and sensitive skin repair comprises the following components in parts by weight: 2.5 parts of Sophora flavescens extract; Scutellaria baicalensis extract 5-15 parts; 10 parts of white peony extract; Grapefruit extract 0.5-5 parts; 2-5 parts of pomegranate extract.

[0009] More preferably, the composition for antibacterial, anti-inflammatory, soothing, and sensitive skin repair comprises the following components in parts by weight: 2.5 parts of Sophora flavescens extract; 10-15 parts of Scutellaria baicalensis extract; 10 parts of white peony extract; Grapefruit extract 0.5-5 parts; 4-5 parts of pomegranate extract.

[0010] Most preferably, the composition for antibacterial, anti-inflammatory, soothing, and sensitive skin repair comprises the following components in parts by weight: 2.5 parts of Sophora flavescens extract; 10 parts of Scutellaria baicalensis extract; 10 parts of white peony extract; Grapefruit extract 0.5 parts; Five parts of pomegranate extract.

[0011] The Sophora flavescens used in this invention is the dried root of Sophora flavescens Ait., a legume, which has the effects of clearing heat and drying dampness, and killing parasites. The main chemical components of Sophora flavescens are alkaloids and flavonoids, and the main active ingredients are matrine and oxymatrine, which have pharmacological effects and efficacy in many aspects, including antibacterial, anti-inflammatory, antitumor, antirheumatic, and anti-allergic properties.

[0012] The Scutellaria baicalensis used in this invention is the dried root of Scutellaria baicalensis Georgi, a plant belonging to the Lamiaceae family. It has the effects of clearing heat and drying dampness, purging fire and detoxifying. Scutellaria baicalensis mainly contains flavonoids such as baicalin, wogonin, baicalin glycoside, and wogonin glycoside, which have pharmacological effects such as antioxidation, anti-inflammation, antibacterial, and antitumor activity.

[0013] The white peony used in this invention is the dried root of Paeonia lactiflora Pall., a plant in the Ranunculaceae family. It has the effects of nourishing blood and regulating menstruation, astringing yin and stopping sweating, soothing the liver and relieving pain, and calming liver yang. White peony contains monoterpenes and their glycosides, triterpenes, flavonoids, tannins, polysaccharides, and other major components. Among them, the most studied active components are paeoniflorin, oxypaeoniflorin, paeoniflorin lactone, gallic acid, and benzoylpaeoniflorin, which have pharmacological effects such as anti-inflammatory, analgesic, antidepressant, hypoglycemic, antioxidant, immunomodulatory, and antitumor properties.

[0014] The grapefruit used in this invention is the dried outer peel of immature or nearly mature grapefruit (Citrus grandis (L.) Osbeck) and grapefruit (C. paradisi Macfad.) belonging to the Rutaceae family. In addition to essential nutrients such as water, vitamins, and minerals, grapefruit peel also contains flavonoids such as naringin and hesperidin, as well as various physiologically active components such as limonenes, coumarins, essential oils, natural pigments, and dietary fiber, exhibiting pharmacological effects including antioxidant, anti-inflammatory, analgesic, antiviral, and antibacterial properties.

[0015] The pomegranate used in this invention is the dried pericarp of Punica granatum L., a plant of the Punicaceae family. It has astringent and antidiarrheal properties, as well as hemostatic effects. Pomegranate pericarp mainly contains tannins and flavonoids, and contains small amounts of polysaccharides and amino acid compounds, exhibiting pharmacological effects such as antioxidant, antiviral, antitumor, hypoglycemic, and antibacterial properties.

[0016] Preferably, the composition further includes the following components: solvent and pH adjuster.

[0017] Preferably, the solvent includes at least one of dipropylene glycol, propylene glycol, butylene glycol, glycerol, and water.

[0018] Preferably, the pH adjuster is an aqueous solution of sodium hydroxide.

[0019] Secondly, the present invention provides a method for preparing a composition that has antibacterial and anti-inflammatory properties, soothes inflammation, and repairs sensitive skin, comprising the following steps: mixing Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate extract to obtain the composition.

[0020] Thirdly, the present invention provides the application of a composition that has antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties in the preparation of cosmetics with anti-inflammatory, soothing, and skin-repairing effects.

[0021] Preferably, the composition for antibacterial, anti-inflammatory, soothing, and sensitive skin repair is added to cosmetics at a mass fraction of 0.01-10%.

[0022] Compared with the prior art, the present invention has the following beneficial effects: This invention utilizes a composition prepared from extracts of Sophora flavescens, Scutellaria baicalensis, Paeonia lactiflora, grapefruit, and pomegranate. The composition features matrine, baicalin, paeoniflorin, naringin, and punicein as the main active ingredients, which work synergistically to achieve significant anti-inflammatory, soothing, and skin-repairing effects on sensitive skin. Attached Figure Description

[0023] Other features, objects, and advantages of the present invention will become more apparent from the following detailed description of non-limiting embodiments with reference to the accompanying drawings: Figure 1 Photographs of the degranulation test in the blank group; Figure 2 Photos of the departicle removal test of the model group; Figure 3 Photographs of the degranulation test in the positive group; Figure 4 This is a photograph of the departicle test of the sample group in Example 1. Detailed Implementation

[0024] The present invention will now be described in detail with reference to specific embodiments. These embodiments will help those skilled in the art to further understand the present invention, but do not limit the invention in any way. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention. These all fall within the scope of protection of the present invention.

[0025] The terms "preferred," "more preferably," and "more suitable" used in this invention refer to embodiments of the invention that provide certain beneficial effects under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. Furthermore, the description of one or more preferred embodiments does not imply that other embodiments are unavailable, nor is it intended to exclude other embodiments from the scope of this invention.

[0026] It should be understood that, except in any operational instance or otherwise indicated, all figures representing the amounts of ingredients used, for example, in the specification and claims, should be understood to be modified in all cases by the term "about". Therefore, unless otherwise stated, the numerical parameters set forth in the following specification and appended claims are approximations varying with the desired performance to be obtained according to the invention. It is not at all an attempt to limit the application of the doctrine of equivalents to the scope of the claims; each numerical parameter should be interpreted at least according to the number of significant figures reported and by applying ordinary rounding techniques.

[0027] Although the numerical ranges and parameters illustrating the broad scope of the invention are approximate, the values ​​listed in the specific examples are reported as precisely as possible. However, any numerical value inherently contains some error that is necessarily caused by the standard deviation found in their respective test measurements.

[0028] The following embodiments provide a composition containing pungent glycosides with soothing effects, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The Sophora flavescens extract (matrine content ≥98%), Scutellaria baicalensis extract (baicalin content ≥95%), Paeonia lactiflora extract (paeoniflorin ≥50%), grapefruit extract (naringin content ≥50%), and pomegranate extract (pungent glycoside content ≥40%) of the present invention conform to the general definition in the art and are widely used as cosmetic raw materials in the cosmetic field.

[0029] This application provides a general and / or specific description of the materials and experimental methods used in the experiments.

[0030] In the following examples, all raw materials and reagents used are commercially available products.

[0031] Example 1 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate extract. The weight proportions of each component are shown in Table 1. The preparation of the composition is mainly carried out according to the following steps: (1) Weigh 2.5 parts of Sophora flavescens extract (matrine content ≥98%, Nanjing Chunqiu Bioengineering Co., Ltd.) and 10 parts of Scutellaria baicalensis extract (baicalin content ≥95%, Nanjing Chunqiu Bioengineering Co., Ltd.), add 700 parts of 1,3-propanediol and 100 parts of water, set the stirring temperature to 40℃, the stirring speed to 400 rpm, and the stirring time to 20 min, and gradually add 5 parts of 1% NaOH aqueous solution to completely dissolve the powder, and obtain a mixed solution of Sophora flavescens extract and Scutellaria baicalensis extract, which is solution A, for later use.

[0032] (2) Weigh 10 parts of white peony extract (paeoniflorin content ≥50%, Xi'an Haoxuan Biotechnology Co., Ltd.), 3 parts of grapefruit extract (naringin content ≥50%, Nanjing Chunqiu Bioengineering Co., Ltd.), and 5 parts of pomegranate extract (punicin content ≥40%, Nanjing Chunqiu Bioengineering Co., Ltd.). Add 195 parts of water, set the stirring temperature to 30℃ and the stirring speed to 400 rpm, and stir continuously until the solution changes from turbid to clear and transparent.

[0033] (3) Add the B solution obtained in step (2) to the Sophora flavescens extract solution obtained in step (1), and add water to make up the balance based on 1000 parts of total solution. Set the stirring temperature to 30°C and the stirring speed to 400 rpm, stir for 10 min, mix thoroughly, and then filter with a nylon filter membrane with a pore size of 1 μm to obtain the composition.

[0034] Example 2 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The weight proportions of each component are shown in Table 1. The preparation method of the composition is the same as in Example 1.

[0035] Example 3 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The weight proportions of each component are shown in Table 1. The preparation method of the composition is the same as in Example 1.

[0036] Example 4 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The weight proportions of each component are shown in Table 1. The preparation method of the composition is the same as in Example 1.

[0037] Example 5 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The weight proportions of each component are shown in Table 1. The preparation method of the composition is the same as in Example 1.

[0038] Example 6 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The weight proportions of each component are shown in Table 1. The preparation method of the composition is the same as in Example 1.

[0039] Example 7 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The weight proportions of each component are shown in Table 1. The preparation method of the composition is the same as in Example 1.

[0040] Example 8 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The weight proportions of each component are shown in Table 1. The preparation method of the composition is the same as in Example 1.

[0041] Example 9 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The weight proportions of each component are shown in Table 1. The preparation method of the composition is the same as in Example 1.

[0042] Example 10 This embodiment provides a composition with antibacterial, anti-inflammatory, anti-inflammatory, and skin-repairing properties, comprising Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate peel extract. The weight proportions of each component are shown in Table 1. The preparation method of the composition is the same as in Example 1.

[0043] Table 1 Comparative Example 1 This comparative example provides a composition comprising only Sophora flavescens extract. The preparation method of the composition is as follows: (1) Weigh 28 parts of Sophora flavescens extract (matrine content ≥98%, Xi'an Haoxuan Biotechnology Co., Ltd.), add 700 parts of 1,3-propanediol, add water to make up to 1000 parts, set the stirring temperature to 30℃ and the stirring speed to 400rpm, stir continuously until the solution changes from turbid to clear and transparent, and then filter with a nylon filter membrane with a pore size of 1μm to obtain the soothing composition.

[0044] Comparative Example 2 This comparative example provides a composition comprising only Scutellaria baicalensis extract. The preparation method of the composition is as follows: (1) Weigh 28 parts of Scutellaria baicalensis extract (baicalin content ≥95%, Nanjing Chunqiu Bioengineering Co., Ltd.), add 700 parts of 1,3-propanediol, add 200 parts of water, set the stirring temperature to 40℃ and the stirring speed to 400rpm, gradually add 5 parts of 1% NaOH aqueous solution to completely dissolve the powder, add water to make up to 1000 parts, stir for 20 min, mix thoroughly, and then filter with a nylon filter membrane with a pore size of 1μm to obtain the soothing composition.

[0045] Comparative Example 3 This comparative example provides a composition comprising only white peony extract. The preparation method of the composition is as follows: Weigh 28 parts of white peony extract (paeoniflorin content ≥50%, Xi'an Haoxuan Biotechnology Co., Ltd.), add 700 parts of 1,3-propanediol, add water to make up to 1000 parts, set the stirring temperature to 30℃ and the stirring speed to 400 rpm, so that the powder is completely dissolved, stir for 20 min, mix thoroughly, and then filter through a nylon filter membrane with a pore size of 1μm to obtain the soothing composition.

[0046] Comparative Example 4 This comparative example provides a composition that differs from Example 1 only in that: no Sophora flavescens extract was added in this comparative example, and 12.5 parts of Scutellaria baicalensis extract were used. The preparation method of the composition is the same as that in Example 1.

[0047] Comparative Example 5 This comparative example provides a composition that differs from Example 1 only in that: Scutellaria baicalensis extract was not added to this comparative example, and 12.5 parts of Sophora flavescens extract were used. The preparation method of the composition is the same as that of Example 1.

[0048] Comparative Example 6 This comparative example provides a composition that differs from Example 1 only in that: no white peony extract was added in this comparative example, and 20 parts of scutellaria baicalensis extract were used. The preparation method of the composition is the same as that in Example 1.

[0049] Comparative Example 7 This comparative example provides a composition that differs from Example 1 only in that: grapefruit extract was not added in this comparative example, and 5.5 parts of pomegranate peel extract were used. The preparation method of the composition is the same as that of Example 1.

[0050] Comparative Example 8 This comparative example provides a composition that differs from Example 1 only in that: pomegranate peel extract was not added in this comparative example, and 5.5 parts of grapefruit extract were used. The preparation method of the composition is the same as that of Example 1.

[0051] Comparative Example 9 This comparative example provides a composition that differs from Example 7 only in that 1 part grapefruit extract and 7 parts pomegranate peel extract are added. The preparation method of the composition is the same as that of Example 1.

[0052] Comparative Example 10 This comparative example provides a composition that differs from Example 7 only in that 7 parts of grapefruit extract and 1 part of pomegranate peel extract are added. The preparation method of the composition is the same as that of Example 1.

[0053] Comparative Example 11 This comparative example provides a composition that differs from Example 9 only in that 13 parts of Scutellaria baicalensis extract, 15 parts of Paeonia lactiflora extract, and 2 parts of pomegranate peel extract are added to this comparative example. The preparation method of the composition is the same as that of Example 1.

[0054] Comparative Example 12 This comparative example provides a composition that differs from Example 9 only in that 7.5 parts of Sophora flavescens extract and 5 parts of Paeonia lactiflora extract are added. The preparation method of the composition is the same as that of Example 1.

[0055] Comparative Example 13 This comparative example provides a composition that differs from Example 6 only in that 17 parts of Scutellaria baicalensis extract and 3 parts of Paeonia lactiflora extract are added. The preparation method of the composition is the same as that of Example 1.

[0056] Table 2 Efficacy verification Verification of the effect of the composition of Example 1 on LPS-induced macrophage cytokines (1) Sample preparation The compositions prepared in Examples 1-10 and Comparative Examples 1-13 were added to PBS solution to prepare test samples at a final concentration of 0.1%. Dexamethasone was used as a positive control and added to PBS solution to prepare a positive control sample.

[0057] (2) Cell culture According to the appropriate inoculation density (1×10 5 RAW264.7 macrophages (purchased from Beina Chuanglian) were seeded into 24-well plates and cultured in an incubator (37℃, 5%CO2, 95%RH) for about 24 h.

[0058] (3) Cell-based drug delivery When the cell deposition rate in the 24-well plates reached 40%–50%, the cells were divided into groups and administered the drug. Each group had three replicates. Cell culture medium containing each test sample (final concentration of each test sample was 0.10%, serving as the experimental group), a positive control sample (100 μg / mL dexamethasone, serving as the positive control group), and an equal volume of PBS solution (serving as the model group) was added. The blank control group also had an equal volume of PBS solution added to its cell culture medium. Each group had three replicates. After drug administration, the 24-well plates were incubated in an incubator (37℃, 5% CO2) for 2 h.

[0059] (4) Macrophage stimulation After 2 h of grouped drug administration and culture, LPS working solution prepared with the corresponding test substance working solution was added to the well plates of each administered experimental group, positive control group, and model group according to the experimental design. The well plates were shaken left and right to mix the drug in the well plates. The final concentration of LPS was 1 μg / mL. The plates were then incubated in an incubator (37℃, 5% CO2) for 22 h. No LPS working solution was added to the blank control group.

[0060] (5) Determination of the effect of LPS on the content of inflammatory cytokines in macrophages After incubation, the cell culture supernatant was collected in EP tubes and stored at -80°C. TNF-α and IL-6 were detected and analyzed according to the ELISA kit instructions. Before the formal detection, a dilution ratio needed to be set and a preliminary experiment conducted to determine the optimal dilution ratio for the ELISA detection group, ensuring that the ELISA values ​​fell within the range of the standard curve. The test results are shown in Table 3.

[0061] Table 3 Results of macrophage inflammatory cytokine assay Note: Compared with the model group, # indicates p < 0.05, ## indicates p < 0.01, and ### indicates p < 0.001; compared with Example 1 group, This indicates that p < 0.05. This indicates that p < 0.01. This indicates that p < 0.001.

[0062] As shown in Table 3, compared with the blank group, the TNF-α content in the model group was 26626.08±939.84 pg / mL ( P <0.01), and the IL-6 content was 1539.41±6.5 pg / mL ( P <0.001 indicates successful model establishment. Compared with the model group, the levels of TNF-α and IL-6 in the positive control group were significantly decreased ( P <0.001).

[0063] A comparison of Example 1 with Comparative Examples 1-3 shows that when any one of the following extracts—Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate extract—is used alone, the TNF-α and IL-6 contents are significantly higher than in Example 1. A comparison of Example 1 with Comparative Examples 4-8 shows that even when the compositions lack Sophora flavescens extract, Scutellaria baicalensis extract, or Paeonia lactiflora extract, the TNF-α and IL-6 contents are still significantly higher than in Example 1. This demonstrates that all five components in the composition of this invention are indispensable and have a synergistic effect in reducing TNF-α and IL-6 contents.

[0064] Further comparison of Example 7 with Comparative Examples 9-10 shows that excessively high levels of pomegranate extract or grapefruit extract significantly increased TNF-α and IL-6 levels. Comparison of Example 9 with Comparative Examples 11-12 shows that excessively high levels of white peony extract or sophora flavescens extract significantly increased TNF-α and IL-6 levels. Comparison of Example 6 with Comparative Example 13 shows that excessively high levels of scutellaria baicalensis extract also significantly increased TNF-α and IL-6 levels. Therefore, it is evident that within specific ranges, the content of these five herbal extracts can further reduce TNF-α and IL-6 levels.

[0065] Verification of the effect of the composition of Example 2 on mast cell degranulation (1) Operation method P815 cells in logarithmic growth phase (purchased from Beina Biotechnology, mouse mast cell tumor cells) were collected and stored at a cell density of 1×10⁻⁶. 5 Cells were seeded per well in 24-well culture plates. After culturing for 24 h in an incubator (37°C, 5% CO2), drug treatment was administered. Blank control group (BC), negative control group (NC), positive control group (PC: 1 mg / mL sodium cromoglycate), and sample groups were set up using compositions prepared in Examples 1-10 and Comparative Examples 1-13. After drug treatment, the sample groups were incubated for 24 h. Except for the BC group, all other groups were induced for 30 min with 10 μg / mL C48 / 80, and the reaction was terminated by ice bath. Cell degranulation was observed and photographed under an inverted microscope. The degranulation rate was statistically calculated using Image Pro Plus software.

[0066] (2) Effect of raw materials on degranulation of P815 cells Compound 48 / 80 can induce mast cell degranulation and release inflammatory mediators. Mast cell degranulation is closely related to the inflammatory response. C48 / 80 was used to induce degranulation in P815 cells after sample treatment. The degranulation phenomenon was observed and recorded, and its soothing efficacy was evaluated by the sample's ability to inhibit degranulation. Normal mast cells are round or oval, with some adherent cells being spindle-shaped, having clear cell outlines, and the cytoplasm filled with high-refractive-index granules. Conversely, degranulated cells have wrinkled edges and incomplete morphology; severely degranulated cells have almost completely broken cell membranes. The degranulation measurement results for each group are shown in Table 4. Typical photographs of degranulated cell morphology in the blank group, model group, positive group, and sample group of Example 1 are shown in Table 4. Figure 1 , Figure 2 , Figure 3 and Figure 4 .

[0067] Table 4 Results of mast cell degranulation assay Note: Compared with the model group, # indicates p < 0.05, ## indicates p < 0.01, and ### indicates p < 0.001; compared with Example 1 group, This indicates that p < 0.05. This indicates that p < 0.01. This indicates that p < 0.001.

[0068] Compared with the control group, the cell degranulation rate in the model group was (87.52%±0.90%). P <0.01 indicates successful model establishment. Compared with the model group, the cell degranulation rate significantly decreased to (9.92%±0.73%) after treatment with sodium cromoglycate (positive control group). P <0.01). Compared with the model group, Examples 1-10 and Comparative Examples 1-13 all reduced the degranulation rate of P815 cells ( P <0.01), and Examples 1-10 showed a more prominent ability to inhibit mast cell degranulation, especially Example 1, where the degranulation rate of P815 cells was reduced to (16.35%±0.45%), demonstrating excellent soothing effects.

[0069] A comparison of Example 1 with Comparative Examples 1-3 shows that when any one of the following extracts—Sophora flavescens extract, Scutellaria baicalensis extract, Paeonia lactiflora extract, grapefruit extract, and pomegranate extract—is used alone, the degranulation rate of P815 cells is significantly higher than that of Example 1. A comparison of Example 1 with Comparative Examples 4-8 shows that even when the composition lacks Sophora flavescens extract, Scutellaria baicalensis extract, or Paeonia lactiflora extract, the degranulation rate of P815 cells is still significantly higher than that of Example 1. This demonstrates that all five components in the composition of the present invention are indispensable and have a synergistic effect in reducing the degranulation rate of P815 cells.

[0070] Further comparison of Example 7 with Comparative Examples 9-10 shows that excessively high levels of pomegranate extract or grapefruit extract significantly increased the degranulation rate of P815 cells. Comparison of Example 9 with Comparative Examples 11-12 shows that excessively high levels of white peony extract or sophora flavescens extract significantly increased the degranulation rate of P815 cells. Comparison of Example 6 with Comparative Example 13 shows that excessively high levels of scutellaria baicalensis extract also significantly increased the degranulation rate of P815 cells. Therefore, it is evident that when the content of the five herbal extracts is within a specific range, the degranulation rate of P815 cells can be further reduced, thereby improving the soothing effect.

[0071] Antibacterial rate test of the composition in Example 3 According to GB 15979—2024 standard, the composition prepared in the examples was tested for its 5-minute inhibition rate against Staphylococcus aureus ATCC6538, Escherichia coli 8099, and Candida albicans (all strains were purchased from Guangdong Huankai Microbial Technology Co., Ltd.). Add 0.5 mL of freshly prepared bacterial suspension to 4.5 mL of sample solution, mix well, and start timing. Continue for the time specified in the instructions. Use a quantitative pipette to add 0.5 mL of the bacterial suspension to a 4.5 mL test tube containing the neutralizing agent, mix thoroughly, and allow to neutralize for 10 min. Then, perform a 10-fold serial dilution. Select an appropriate dilution and inoculate 1.0 mL onto each Petri dish, inoculating two Petri dishes per tube. Pour 15 mL to 20 mL of nutrient agar medium (for bacteria) or Sabouraud agar medium (for yeast) that has been melted at 40 ℃~45 ℃ into the Petri dishes containing the sample solution. Rotate the Petri dishes to mix thoroughly. After the agar solidifies, invert the Petri dishes and incubate at 36 ℃±1 ℃ for 48 h (for bacteria) or 72 h (for yeast). Then, count the viable colonies. Simultaneously, a diluent was used to replace the sample in parallel experiments as a positive control, with a recovered bacterial count of 1.0 × 10⁻⁶. 4 CFU / mL~9.0×10 4 CFU / mL. Repeat the test 3 times and calculate the sterilization rate.

[0072] Table 5. Results of Antibacterial Rate Test of the Composition As can be seen from the results in Table 5, the compositions prepared in the embodiments of the present invention all have certain antibacterial abilities. In particular, the compositions prepared in Examples 1 and 6 have the highest antibacterial rates against Staphylococcus aureus, Escherichia coli, and Candida albicans.

[0073] Human efficacy evaluation experiment of the composition in Example 4 for repairing sensitive skin. Soothing and repairing face creams were prepared using the compositions prepared in the examples and comparative examples, respectively. The specific ingredient composition and percentage ratio of the face creams are shown in Table 6. A face cream prepared without the addition of the blank matrix of the compositions prepared in the examples and comparative examples was used as a blank control.

[0074] Table 6 Study Subjects: Several volunteers with sensitive skin were selected through a lactic acid stinging test. Inclusion Criteria: Female, aged 30-60 years, with sensitive skin; in good health, able to cooperate with the experiment, serious attitude, able to use cosmetics according to regulations and cooperate with staff to complete the evaluation work as required; possessing certain expressive ability and able to truthfully reflect their feelings after use; willing to participate and sign the informed consent form, able to strictly abide by the requirements of the study protocol, use the products as required by the study protocol, and complete the follow-up.

[0075] Exclusion criteria: pregnant or breastfeeding women, those with facial skin damage or skin diseases that affect the observation of facial condition, those who have used laser, chemical peel, botulinum toxin, dermal filler or facelift surgery on the face, those who have sunburn within the past month, and those who have participated in other facial clinical studies or received treatment from dermatologists in the present or past 3 months.

[0076] Termination and exclusion criteria: Subject requests to discontinue the trial; subject compliance is poor; the trial cannot continue due to adverse reactions or special physiological or pathological changes; use of other skin care products that may affect the trial, excessive exposure to ultraviolet radiation, etc.

[0077] Product Use and Testing Arrangements: Before the test, all subjects cleaned their faces and dried them with lint-free absorbent paper towels. After sitting quietly for 30 minutes in a constant temperature and humidity environment ((21±1)℃, relative humidity (50±10)%), the subjects were measured by technicians. After grouping the subjects, the transepidermal water loss rate and facial hemoglobin content were measured before product use and recorded as initial values. After sample distribution, subjects were regularly reminded to use the samples as required. The experiment was arranged in autumn, starting in November. A half-face experiment was conducted. After washing and drying their faces morning and evening, subjects applied a soothing repair cream rich in the composition of the example or comparative example to their right face once, and a blank control cream base to their left face once as a control. The amount applied to both sides was equal each time, and the cream was applied evenly. The treatment lasted for 4 consecutive weeks. During the experiment, the products were not used concurrently with other soothing skincare products. Subjects were required to have follow-up visits at the same time each day, at designated test time points (2 weeks and 4 weeks after product use). Image acquisition, transepidermal water loss rate, and facial hemoglobin content were measured and recorded as values. The product was not used on the day of the test, and the entire test period was 4 weeks.

[0078] Instrument testing: Transepidermal water loss: At each visit point, the transepidermal water loss rate (TEWL value) of the skin in each test area was measured using a VapoMeter SWL5201 transepidermal water loss meter.

[0079] Facial hemoglobin content measurement: At each visit point, the hemoglobin content (EI value) of each test area was measured using a Mexameter MX18 skin melanin and hemoglobin analyzer.

[0080] Formulas for calculating the rate of change of TEWL and EI values: Rate of change = (before use - after use) / before use 100% The test results are shown in Table 7.

[0081] Table 7 Clinical Trial Data The experimental results showed that after using the soothing and repairing face creams of Examples 1, 6, 7, and 9 for 2 and 4 weeks, the transepidermal water loss (TEWL) of the skin was significantly reduced compared with the baseline value (D0), with improvement rates of 22.26-29.89%, 21.49-23.14%, 19.94-22.51%, and 20.28-21.90%, respectively. After using the samples for 2 and 4 weeks, the facial hemoglobin value (EI) was significantly improved compared with the baseline value (D0), with improvement rates of 9.30-11.39%, 9.54-10.77%, 8.70-10.82%, and 8.86-11.44%, respectively. Further comparison results show that the soothing and repairing cream in the example is more effective than the soothing and repairing cream in the comparative examples. While the transepidermal water loss (TEWL) of the soothing and repairing creams in comparative examples 4, 7, 10, 11, and 13 showed significant improvement compared to the baseline value (D0) after 2 and 4 weeks of use, the improvement rate was significantly lower than that of the soothing and repairing cream in the example. After 2 and 4 weeks of use, the facial hemoglobin (EI) value of the soothing and repairing creams in comparative examples 4, 7, 10, and 11 did not show significant changes compared to the baseline value (D0); however, while the soothing and repairing cream in comparative example 13 showed significant improvement in facial hemoglobin (EI) value compared to the baseline value (D0) after 2 and 4 weeks of use, the improvement rate was significantly lower than that of the soothing and repairing cream in the example. In the blank control group, after 2 and 4 weeks of use, there were no significant changes in transepidermal water loss (TEWL) and facial hemoglobin (EI) compared with the baseline (D0).

[0082] The above experimental results show that the soothing composition prepared in this invention has antibacterial and anti-inflammatory effects, soothes inflammation, and repairs sensitive skin, and can be used in cosmetics with soothing effects.

[0083] This invention has many specific applications, and the above description is only a preferred embodiment. It should be noted that the above embodiments are for illustrative purposes only and are not intended to limit the scope of protection of this invention. For those skilled in the art, several improvements can be made without departing from the principle of this invention, and these improvements should also be considered within the scope of protection of this invention.

Claims

1. A bacteriostatic anti-inflammatory, soothing inflammation, repairing sensitive skin composition, characterized in that, The composition comprises the following components in parts by weight: Sophora flavescens extract 1-5 parts; Scutellaria extract 2-15 parts; Radix Paeoniae Alba extract 5-10 parts; Grapefruit extract 0.2-5 parts; Pomegranate extract 1-5 parts.

2. The anti-bacterial, anti-inflammatory, soothing inflammatory, repairing sensitive skin composition containing punicalagins according to claim 1, characterized in that, The composition comprises the following components in parts by weight: Sophora flavescens extract 2.5 parts; Scutellaria extract 5-15 parts; Radix Paeoniae Alba extract 10 parts; Grapefruit extract 0.5-5 parts; Pomegranate extract 2-5 parts.

3. The anti-bacterial, anti-inflammatory, soothing inflammatory, repairing sensitive skin composition containing punicalagins according to claim 1 or 2, characterized in that, The composition comprises the following components in parts by weight: Sophora flavescens extract 2.5 parts; Scutellaria extract 10-15 parts; Radix Paeoniae Alba extract 10 parts; Grapefruit extract 0.5-5 parts; Pomegranate extract 4-5 parts.

4. The anti-bacterial, anti-inflammatory, soothing inflammatory, repairing sensitive skin composition containing punicalagins according to claim 3, characterized in that, The composition comprises the following components in parts by weight: Sophora flavescens extract 2.5 parts; Scutellaria extract 10 parts; Radix Paeoniae Alba extract 10 parts; Grapefruit extract 0.5 parts; Pomegranate extract 5 parts.

5. The bacteriostatic anti-inflammatory, soothing inflammatory, repairing sensitive skin composition according to claim 1, characterized in that, The composition further comprises The composition further comprises 6. The bacteriostatic anti-inflammatory, soothing inflammatory, repairing sensitive skin composition according to claim 5, characterized in that, The solvent comprises at least one of dipropylene glycol, propylene glycol, butylene glycol, glycerol, and water.

7. The bacteriostatic anti-inflammatory, soothing inflammatory, repairing sensitive skin composition according to claim 5 or 6, characterized in that, The pH regulator is sodium hydroxide aqueous solution.

8. A method for preparing the bacteriostatic anti-inflammatory, soothing inflammatory, repairing sensitive skin composition according to any one of claims 1-7, characterized in that, The composition comprises the following steps: Mixing Sophora flavescens extract, Scutellaria extract, Radix Paeoniae Alba extract, grapefruit extract, and pomegranate extract to obtain the composition.

9. Use of the bacteriostatic anti-inflammatory, inflammation-relieving, and sensitive skin-repairing composition according to any one of claims 1-7 in the preparation of a cosmetic product having the effects of anti-inflammation, inflammation relief, and sensitive skin repair.

10. Use according to claim 9, characterized in that, The bacteriostatic anti-inflammatory, inflammation-relieving, and sensitive skin-repairing composition is added to the cosmetic product in a mass fraction of 0.01-10%.

Images